A multicenter, open-label, phase II/III study to asseses the efficacy, safety and Pharmacokinetics(PK) of macitentan (ACT-064992) in patients with pulmonary arterial hypertension.

Trial Profile

A multicenter, open-label, phase II/III study to asseses the efficacy, safety and Pharmacokinetics(PK) of macitentan (ACT-064992) in patients with pulmonary arterial hypertension.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Actelion Pharmaceuticals; Nippon Shinyaku
  • Most Recent Events

    • 13 May 2016 Primary endpoint has been met. (To evaluate the effect of macitentan on resting pulmonary vascular resistance (PVR) over a 24-week-period), as per an article published in the Circulation Journal.
    • 13 May 2016 Results published in the Circulation Journal
    • 12 Feb 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top